Guaifenesin - Muscle Relaxant - Upper Back Pain
This study is currently recruiting participants.
Verified January 2013 by GlaxoSmithKline
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01562548
First received: March 22, 2012
Last updated: March 7, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Explore the clinical efficacy of 7-day treatment regimens of guaifenesin in order to investigate the evidence that guaifenesin is an effective treatment for upper back/neck/shoulder muscle spasm/stiffness and pain.
| Condition | Intervention |
|---|---|
|
Upper Back Pain |
Drug: Guaifenesin Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | A Proof of Principle Study to Explore the Utility of Guaifenesin in Upper Back Pain |
Resource links provided by NLM:
MedlinePlus related topics:
Back Pain
Drug Information available for:
Guaifenesin
Phenylpropanolamine hydrochloride
Triaminic
Phenylpropanolamine
U.S. FDA Resources
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Vernon-Mior Disability Questionnaire [ Time Frame: Day 1 (Screening), Day 4, Day 7 ] [ Designated as safety issue: No ]Neck Pain & Disability
- Daily Upper Back/Neck/Shoulder Symptom Assessment [ Time Frame: Day 2, Day 4, Day 7, Day 9 (follow-up) ] [ Designated as safety issue: No ]Diary Card
- Global Assessment [ Time Frame: Day 4, Day 7 ] [ Designated as safety issue: No ]Global Upper Back/Neck/Shoulder Assessment
Secondary Outcome Measures:
- AE Assessment [ Time Frame: Day 1 through Day 9 (follow-up) ] [ Designated as safety issue: Yes ]frequency of adverse events (AEs) following treatment with the study medications.
| Estimated Enrollment: | 78 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm 1
Guaifenesin 1 tablet BID
|
Drug: Guaifenesin
high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
|
|
Experimental: Arm 2
Guaifenesin 2 tablets BID
|
Drug: Guaifenesin
high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
|
|
Placebo Comparator: Arm 3
Placebo 1 tablet BID
|
Drug: Placebo
no active ingredient
|
|
Placebo Comparator: Arm 4
Placebo 2 tablets BID
|
Drug: Placebo
no active ingredient
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Paticipant presents with a new episode of acute upper back/neck/shoulder pain and muscle spasm that:
- is at least 30 days from previous episode.
- has an onset occurred within 48 hours of Visit 1.
- has symptoms consistent with a clinical diagnosis as per the physical examination at Visit 1.
- has a subject-rated muscle spasm score and a pain score of at least 40 out of 100 on a 100mm VAS.
- Paticipant has a normal neurological examination.
Exclusion Criteria:
- Medical history: a) Paticipant has a known or suspected intolerance or hypersensitivity to guaifenesin or methocarbamol (or closely related compounds) or any of their stated ingredients. b) Paticipant has history of upper back pain with active hypersensitive spots - trigger point in the muscles of upper back/neck/shoulder/maxillofacial regions. c) Paticipant has a current or recent history of liver and/or kidney disease, neck/back/shoulder injuries, spinal disc disease, myocardial infarction (<12 months from Visit 1) and osteoporosis. d) Subjects have history of other chronic pain e.g. headache, osteoarthritis, arthritis, lower back pain etc.
- Medications: a) Paticipant has used a muscle relaxant or narcotic within 2 weeks of Visit 1. b) Paticipant has used monoamine oxidase inhibitors or selegiline within 2 weeks of Visit 1 c) Currently using tricyclic antidepressants, lithium, anticoagulants, or tramadol.
- Paticipant is involved in a workers compensation case.
- Paticipant is unlikely to refrain from using analgesics, NSAIDs, and other muscle relaxants for the duration of the study, with the exception of cardioprotective doses of aspirin (i.e., ≤ 325 mg/day).
- Paticipant is unlikely to refrain from physical therapy, massage therapy, acupuncture, heat treatment, spas, etc for the duration of the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01562548
Contacts
| Contact: US GSK Clinical Trials Call Center | 877-379-3718 | GSKClinicalSupportHD@gsk.com |
Locations
| United States, California | |
| Med Investigations | Enrolling by invitation |
| Fair Oaks, California, United States, 95628 | |
| San Diego Sports Medicine and Family Health Center | Recruiting |
| San Diego, California, United States, 92120 | |
| Contact: US GSK Clinical Trials Call Center 877-379-3718 info@GSKClinicalSupportHD@gsk.com | |
| Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 info@GSKClinicalSupportHD@gsk.com | |
| United States, Ohio | |
| Radiant Research - Cincinnati | Recruiting |
| Cincinnati, Ohio, United States, 45249 | |
| Contact: US GSK Clinical Trials Call Center 877-379-3718 info@GSKClinicalSupportHD@gsk.com | |
| Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 info@GSKClinicalSupportHD@gsk.com | |
| United States, Texas | |
| Radiant Research, Inc. - TX | Recruiting |
| San Antonio, Texas, United States, 78229 | |
| Contact: US GSK Clinical Trials Call Center 877-379-3718 info@GSKClinicalSupportHD@gsk.com | |
| Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 info@GSKClinicalSupportHD@gsk.com | |
| United States, Utah | |
| J. Lewis Research | Terminated |
| Salt Lake City, Utah, United States, 84109 | |
Sponsors and Collaborators
GlaxoSmithKline
Investigators
| Study Director: | GSK Clinical Trials | GlaxoSmithKline |
More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT01562548 History of Changes |
| Other Study ID Numbers: | A3940666 |
| Study First Received: | March 22, 2012 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by GlaxoSmithKline:
|
upper back/neck/shoulder muscle spasm |
Additional relevant MeSH terms:
|
Back Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Guaifenesin Phenylpropanolamine Chlorpheniramine, phenylpropanolamine drug combination Expectorants Respiratory System Agents Therapeutic Uses Pharmacologic Actions Adrenergic alpha-Agonists Adrenergic Agonists |
Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Appetite Depressants Anti-Obesity Agents Central Nervous System Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Nasal Decongestants Vasoconstrictor Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 16, 2013